Shots:
- The EC has approved Koselugo for the treatment of symptomatic, inoperable plexiform neurofibromas (PN) in adults with neurofibromatosis type 1 (NF1)
- Approval was based on the P-III (KOMET) study assessing Koselugo (PO) vs PBO in 145 adults with NF1 & symptomatic, inoperable PNs across 13 countries incl. North America, South America, Europe, Asia & Australia
- The study met its 1EP, showing an ORR of 20% (14/71) vs 5% (4/74) by cycle 16; PBO pts switched to Koselugo after 12 cycles, while treated patients continued for 12 additional cycles; data presented at ASCO’25 & published in The Lancet
Ref: AstraZeneca | Image: AstraZeneca | Press Release
Related News:- AstraZeneca Reports P-III (Bax24) Trial Data on Baxdrostat for Treatment-Resistant Hypertension
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
